https://orcid.org/0000-0003-1781-3393
References
- Amstutz U, Henricks LM, Offer SM, et al. (2018). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103:210–6.
- Beumer JH, Chu E, Allegra C, et al. (2019). Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy. Clin Pharmacol Ther 105:598–613.
- Bray F, Ferlay J, Soerjomataram I, et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424.
- Center for Drug Evaluation and Research of the U.S. Department of Health and Human Services Food and Drug Administration. 2018. Bioanalytical method validation. Guidance for industry. Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064964.htm [last accessed 2 Aug 2018].
- Chavani O, Jensen BP, Strother RM, et al. (2017). Development, validation and application of a novel liquid chromatography tandem mass spectrometry assay measuring uracil, 5,6-dihydrouracil, 5-fluorouracil, 5,6-dihydro-5-fluorouracil, α-fluoro-β-ureidopropionic acid and α-fluoro-β-alanine in human plasma. J Pharm Biomed Anal 142:125–35.
- da Silva CB, Julio IP, Donadel GE, Martins I. (2016). UPLC-MS/MS method for simultaneous determination of cyclophosphamide, docetaxel, doxorubicin and 5-fluorouracil in surface samples. J Pharmacol Toxicol Methods 82:68–73.
- Kristensen MH, Pedersen P, Mejer J. (2010). The value of dihydrouracil/uracil plasma ratios in predicting 5-fluorouracil-related toxicity in colorectal cancer patients. J Int Med Res 38:1313–23.
- Lee JJ, Beumer JH, Chu E. (2016). Therapeutic drug monitoring of 5-fluorouracil. Cancer Chemother Pharmacol 78:447–64.
- Li J, Chen Y, Zhou P, et al. (2018). Simultaneous determination of the novel anti-tumor candidate drug MDH-7 and 5-fluorouracil in rat plasma by LC-MS/MS: application to pharmacokinetic interactions. J Chromatogr B Analyt Technol Biomed Life Sci 1095:235–40.
- Lu Z, Zhang R, Diasio RB. (1993). Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53:5433–8.
- Matuszewski BK, Constanzer ML, Chavez-Eng CM. (2003). Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 75:3019–30.
- Meulendijks D, Henricks LM, Sonke GS, et al. (2015). Clinical relevance of DPYD variants c.1679T > G, c.1236G > A/HapB3, and c.1601G > A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 16:1639–50.
- Murphy RF, Balis FM, Poplack DG. (1987). Stability of 5-fluorouracil in whole blood and plasma. Clin Chem 33:2299–300.
- Neto OV, Raymundo S, Franzoi MA, et al. (2018). DPD functional tests in plasma, fresh saliva and dried saliva samples as predictors of 5-fluorouracil exposure and occurrence of drug-related severe toxicity. Clin Biochem 56:18–25.
- Pluim D, Jacobs BA, Deenen MJ, et al. (2015). Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Bioanalysis 7:519–29.
- Saif MW, Syrigos K, Mehra R, et al. (2007). Dihydropyrimidine dehydrogenase deficiency (DPD) in GI malignancies: experience of 4-years. Pak J Med Sci 23:832–9.
- Shiokawa R, Lee XP, Yamada M, et al. (2019). High-throughput method to analyze tegafur and 5-fluorouracil in human tears and plasma using hydrophilic interaction liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 33:1906–14.
- van Kuilenburg AB, van Lenthe H, Blom MJ, et al. (1999). Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. Br J Cancer 79:620–6.
- van Kuilenburg AB, van Lenthe H, van Gennip AH. (2006). Activity of pyrimidine degradation enzymes in normal tissues. Nucleosides Nucleotides Nucleic Acids 25:1211–4.
- van Staveren MC, Guchelaar HJ, van Kuilenburg AB, et al. (2013). Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency. Pharmacogenomics J 13:389–95.